However, a recent study analyzing eight patients with coexisting PIK3CA mutations in a cohort of 54 EGFR-mutant advanced NSCLC patients treated with first-generation EGFR-TKIs found that concurrent PIK3CA mutations were significantly associated with a longer PFS compared to wild-type PIK3CA (95). This evidence concerns the gene EGFR and non-small cell lung carcinoma.